Sosei Group Corp. | Income Statement

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
Sales/Revenue
2,070
3,671
8,151
18,901
6,955
Cost of Goods Sold (COGS) incl. D&A
272
166
929
923
1,028
Gross Income
1,798
3,505
7,222
17,978
5,927
SG&A Expense
1,167
2,472
6,285
5,850
8,389
EBIT
631
-
-
12,128
2,462
Unusual Expense
49
86
3,816
1,395
1,000
Non Operating Income/Expense
152
405
26
2,129
2
Interest Expense
-
60
437
192
260
Pretax Income
738
1,301
3,297
12,483
3,702
Income Tax
788
790
1,751
3,331
1,048
Consolidated Net Income
1,526
511
1,546
9,152
2,654
Net Income
1,526
516
1,432
9,310
2,654
Net Income After Extraordinaries
1,526
516
1,432
9,310
2,654
Net Income Available to Common
1,526
516
1,432
9,311
2,654
EPS (Basic)
31.66
9.38
23.39
137.79
37.55
Basic Shares Outstanding
48
55
61
68
71
EPS (Diluted)
31.22
9.28
23.39
137.31
37.55
Diluted Shares Outstanding
49
56
61
68
71
EBITDA
652
1,131
1,851
13,051
1,434
Other Operating Expense
-
-
11
-
-
Non-Operating Interest Income
3
9
4
44
59
Minority Interest Expense
-
5
114
158
-
Equity in Affiliates (Pretax)
-
-
-
229
276

About Sosei Group

View Profile
Address
PMO Hanzomon, 11/F
Tokyo Tokyo 102
Japan
Employees -
Website http://www.sosei.com
Updated 07/08/2019
Sosei Group Corp. engages in the discovery, design, and development of medicines targeting G protein-coupled receptors (GPCRs). Its proprietary StaR (Stabilised Receptor) technology and structure-based drug design (SBDD) platform enables development of drugs for highly validated, yet historically undruggable or challenging GPCRs. The company has multiple programs targeting Alzheimer's disease, schizophrenia, immuno-oncology, migraine, metabolic disease and other rare and specialty indications.